

35.0017
NOV 14 2003
PATENT & TRADEMARK

AF 1600

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/709,249
	Filing Date	November 10, 2000
	First Named Inventor	A.H. Lazarus
	Art Unit	1644
	Examiner Name	G.R. Ewoldt
Total Number of Pages in This Submission	Attorney Docket Number	701826-050990

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Certificate of Mailing; Return Receipt Postcard.
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	The Commissioner is authorized to charge the Nixon Peabody LLP Deposit Account for any fee deficiencies associated with this submission.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	David S. Resnick NIXON PEABODY LLP, 101 Federal Street, Boston, MA 02110	
Signature		
Date	11/12/03	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Washington, DC 20231 on this date:		
Typed or printed name	Nicole M. Gignac	
Signature		Date 11/12/2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Attorney Docket No. 701826-050990

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: LAZARUS, Alan H., et al.
Filed: 10 November 2000
Serial No.: 09/709,249
Title: A METHOD FOR PREVENTING AND
INHIBITING HUMAN HLA ALLOIMMUNE
PLATELET TRANSFUSION
RESPONSE TO
Examiner: EWOLDT, Gerald R.
Group Art Unit: 1644

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)

I hereby certify that this correspondence:

1. Transmittal Form (1 pg.);
2. Amendment Under 37 C.F.R. 1.116 (3 pp.);
3. Return Receipt Postcard;

is on the date shown below being:


MAILING

X deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to MAIL STOP AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22202


Date: Nov. 12, 2003

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.


Signature

Nicole M. Gignac
(type or print name of person certifying)



Attorney Docket No. 701826-050990

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

LAZARUS, Alan H., et al.

Filed:

10 November 2000

Serial No.:

09/709,249

Title:

A METHOD FOR PREVENTING AND
INHIBITING HUMAN HLA ALLOIMMUNE
PLATELET TRANSFUSION

RESPONSE TO

Examiner:

EWOLDT, Gerald R.

Group Art Unit:

1644

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date 11/12/2003

Nicole M. Gignac

(type or print name of person mailing paper)

Nicole M. Gignac
Signature of person mailing paper

RESPONSE UNDER
37 C.F.R. 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1644

MAIL STOP AF

Commissioner for Patents

United States Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. 1.116

Sir:

In response to the Office Action dated September 11, 2003 please further amend the above-identified patent application as follows

A listing of the claims appears on page 2 of this paper.

Remarks/Arguments appear on page 3 of this paper.